• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟喹诺酮类药物在感染性心内膜炎实验模型中的药效学

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.

作者信息

Andes D R, Craig W A

机构信息

William S. Middleton Memorial Veterans Affairs Hospital, Madison, Wisconsin, USA.

出版信息

Clin Infect Dis. 1998 Jul;27(1):47-50. doi: 10.1086/514624.

DOI:10.1086/514624
PMID:9675448
Abstract

We calculated the magnitude of various serum pharmacodynamic parameters for fluoroquinolones in models of experimental endocarditis (EE) described in the literature. Nineteen publications contained data that allowed calculation of these parameters. Data were available for eight fluoroquinolones against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, methicillin-resistant Staphylococcus epidermidis, viridans streptococci, Enterobacter aerogenes, and Pseudomonas aeruginosa in rabbit or rat models. Enterococci were excluded because of poor bactericidal activity. A 24-hour area under the concentration curve (AUC)/minimal inhibitory concentration (MIC) ratio > or = 100, a peak level/MIC ratio > 8, and continuous levels above the time were associated with a significantly lower number of cfu per vegetation after 3-6 days of therapy. The 24-hour AUC/MIC exhibited the best linear correlation with cfu per vegetation after 3-6 days of therapy (r2 = 45%). The pharmacodynamic parameters predictive of efficacy for fluoroquinolones in the treatment of experimental endocarditis are similar to those for other infectious models.

摘要

我们计算了文献中描述的实验性心内膜炎(EE)模型中氟喹诺酮类药物各种血清药效学参数的大小。19篇出版物包含可用于计算这些参数的数据。在兔或大鼠模型中,有针对对甲氧西林敏感的金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、耐甲氧西林表皮葡萄球菌、草绿色链球菌、产气肠杆菌和铜绿假单胞菌的8种氟喹诺酮类药物的数据。由于杀菌活性差,肠球菌被排除在外。治疗3 - 6天后,24小时浓度曲线下面积(AUC)/最低抑菌浓度(MIC)比值≥100、峰浓度/MIC比值>8以及持续高于该时间的血药浓度与每赘生物的菌落形成单位(cfu)数量显著减少相关。治疗3 - 6天后,24小时AUC/MIC与每赘生物的cfu呈现出最佳的线性相关性(r2 = 45%)。氟喹诺酮类药物治疗实验性心内膜炎的药效学预测疗效参数与其他感染模型相似。

相似文献

1
Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.氟喹诺酮类药物在感染性心内膜炎实验模型中的药效学
Clin Infect Dis. 1998 Jul;27(1):47-50. doi: 10.1086/514624.
2
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.利用三株铜绿假单胞菌和体外药效学模型,将24小时浓度-时间曲线下面积与最低抑菌浓度之比作为氟喹诺酮类抗菌效果的一般预测指标。
Antimicrob Agents Chemother. 1996 Mar;40(3):627-32. doi: 10.1128/AAC.40.3.627.
3
Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.体外动态模型中与曲线下面积/MIC比值相关的抗葡萄球菌效应:七种氟喹诺酮类药物的预测断点与临床可达到值
Antimicrob Agents Chemother. 2005 Jul;49(7):2642-7. doi: 10.1128/AAC.49.7.2642-2647.2005.
4
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.加替沙星对肺炎链球菌的药效学评估。
Antimicrob Agents Chemother. 2001 Jul;45(7):2092-7. doi: 10.1128/AAC.45.7.2092-2097.2001.
5
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.在兔组织笼模型中肺炎链球菌对反复暴露于莫西沙星或左氧氟沙星的反应
Antimicrob Agents Chemother. 2001 Mar;45(3):794-9. doi: 10.1128/AAC.45.3.794-799.2001.
6
Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
Pharmacotherapy. 2000 Apr;20(4):417-28. doi: 10.1592/phco.20.5.417.35062.
7
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.眼部药代动力学/药效学贝西沙星、莫西沙星和加替沙星在给色素兔局部给药后的表现。
J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58. doi: 10.1089/jop.2010.0054.
8
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.莫西沙星和左氧氟沙星对肺炎链球菌、金黄色葡萄球菌、肺炎克雷伯菌和大肠杆菌的药效学:体外动力学模型中静脉给药后人体血浆浓度的模拟
J Antimicrob Chemother. 2006 Nov;58(5):960-5. doi: 10.1093/jac/dkl356. Epub 2006 Aug 26.
9
Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.利奈唑胺在体外动态模型中对金黄色葡萄球菌的药效学研究
Int J Antimicrob Agents. 2009 Mar;33(3):251-4. doi: 10.1016/j.ijantimicag.2008.09.006. Epub 2008 Dec 17.
10
Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.加雷沙星治疗草绿色链球菌引起的实验性心内膜炎。
Antimicrob Agents Chemother. 2006 Apr;50(4):1263-7. doi: 10.1128/AAC.50.4.1263-1267.2006.

引用本文的文献

1
In vivo studies on antibiotic combination for the treatment of carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis protocol.体内研究抗生素联合治疗耐碳青霉烯类革兰氏阴性菌:一项系统评价和荟萃分析方案
BMJ Open Sci. 2020 Jul 21;4(1):e100055. doi: 10.1136/bmjos-2019-100055. eCollection 2020.
2
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.在小鼠肺部感染模型中对达氟沙星针对金黄色葡萄球菌、肺炎链球菌和肺炎克雷伯菌的体内药效学靶点评估
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9. doi: 10.1128/AAC.00647-16. Print 2016 Aug.
3
PK/PD models in antibacterial development.
抗菌药物研发中的 PK/PD 模型。
Curr Opin Microbiol. 2013 Oct;16(5):573-9. doi: 10.1016/j.mib.2013.06.010. Epub 2013 Jul 18.
4
Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.抗菌药物在儿童和青少年脑脊液中的药代动力学。
Paediatr Drugs. 2013 Apr;15(2):93-117. doi: 10.1007/s40272-013-0017-5.
5
In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.在金黄色葡萄球菌兔关节炎实验模型中,莫西沙星与氯唑西林和万古霉素的体内疗效比较。
Antimicrob Agents Chemother. 2007 Sep;51(9):3401-3. doi: 10.1128/AAC.01520-06. Epub 2007 Jun 18.
6
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.地塞米松作为莫西沙星的辅助治疗可减轻金黄色葡萄球菌所致实验性主动脉瓣心内膜炎中的瓣膜破坏。
Antimicrob Agents Chemother. 2007 Aug;51(8):2848-54. doi: 10.1128/AAC.01376-06. Epub 2007 Jun 11.
7
Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.加雷沙星治疗草绿色链球菌引起的实验性心内膜炎。
Antimicrob Agents Chemother. 2006 Apr;50(4):1263-7. doi: 10.1128/AAC.50.4.1263-1267.2006.
8
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.应用体外感染模型和模拟对伤寒沙门氏菌血清型伤寒杆菌氟喹诺酮类药物断点进行重新评估。
Antimicrob Agents Chemother. 2005 May;49(5):1775-81. doi: 10.1128/AAC.49.5.1775-1781.2005.
9
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.抗感染药物的药代动力学和药效学问题:杀菌曲线与最低抑菌浓度
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004.
10
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.加替沙星治疗金黄色葡萄球菌或草绿色链球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2004 Jan;48(1):86-92. doi: 10.1128/AAC.48.1.86-92.2004.